The Experts below are selected from a list of 276 Experts worldwide ranked by ideXlab platform

B. A. De Jong - One of the best experts on this subject based on the ideXlab platform.

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC Neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Background Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. Methods/design In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. Trial registration This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): A study protocol for a randomised controlled trial
    Multiple Sclerosis Journal, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, B. A. De Jong
    Abstract:

    Background: Cognitive deficits frequently occur in patients with multiple sclerosis (MS), which profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the efficacy of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive deficits among MS patients, since this may help to develop and guide effective Cognitive treatments. Method: In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or a control group. Both CRT and MBCT consist of a structured 9-week program. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is subjective Cognitive complaints. Secondary outcome measures are objective Cognitive functioning, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion: To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive functioning among MS patients. In addition, studying the effect of CRT on Cognitive functioning may provide direction to the contradictory evidence that is currently available. This study will also provide information on functional brain network changes in relation to cognition. To conclude, this study may help to understand and treat Cognitive deficits among MS patients.

Ilse M. Nauta - One of the best experts on this subject based on the ideXlab platform.

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC Neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Background Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. Methods/design In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. Trial registration This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): A study protocol for a randomised controlled trial
    Multiple Sclerosis Journal, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, B. A. De Jong
    Abstract:

    Background: Cognitive deficits frequently occur in patients with multiple sclerosis (MS), which profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the efficacy of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive deficits among MS patients, since this may help to develop and guide effective Cognitive treatments. Method: In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or a control group. Both CRT and MBCT consist of a structured 9-week program. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is subjective Cognitive complaints. Secondary outcome measures are objective Cognitive functioning, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion: To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive functioning among MS patients. In addition, studying the effect of CRT on Cognitive functioning may provide direction to the contradictory evidence that is currently available. This study will also provide information on functional brain network changes in relation to cognition. To conclude, this study may help to understand and treat Cognitive deficits among MS patients.

David Shum - One of the best experts on this subject based on the ideXlab platform.

  • Web-based Cognitive Rehabilitation for survivors of adult cancer: A randomised controlled trial.
    Psycho-oncology, 2018
    Co-Authors: Mary Elizabeth Mihuta, Heather J. Green, David Shum
    Abstract:

    Objective: Cognitive dysfunction associated with cancer is frequently reported and can reduce quality of life. This study evaluated a Web‐based Cognitive Rehabilitation Therapy program (eReCog) in cancer survivors compared with a waitlist control group. Methods: Adult cancer survivors with self‐reported Cognitive symptoms who had completed primary treatment at least 6 months prior were recruited. Participants completed telephone screening and were randomly allocated to the 4‐week online intervention or waitlist. Primary outcome was perceived Cognitive impairment assessed with the Functional Assessment of Cancer Therapy—Cognitive Function version 3. Secondary outcomes were additional measures of subjective Cognitive functioning, objective Cognitive functioning, and psychosocial variables. Results: Seventy‐six women were allocated to the intervention (n = 40) or waitlist (n = 36). A significant interaction was found on the instrumental activities of daily living measure of self‐reported prospective memory whereby the intervention group reported a greater reduction in prospective memory failures than the waitlist group. Interaction trends were noted on perceived Cognitive impairments (P = .089) and executive functioning (P = .074). No significant interactions were observed on other measures of objective Cognitive functioning or psychosocial variables. Conclusions: The Web‐based intervention shows promise for improving self‐reported Cognitive functioning in adult cancer survivors. Further research is warranted to better understand the mechanisms by which the intervention might contribute to improved self‐reported cognition.

Luciano Fasotti - One of the best experts on this subject based on the ideXlab platform.

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC Neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Background Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. Methods/design In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. Trial registration This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): A study protocol for a randomised controlled trial
    Multiple Sclerosis Journal, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, B. A. De Jong
    Abstract:

    Background: Cognitive deficits frequently occur in patients with multiple sclerosis (MS), which profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the efficacy of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive deficits among MS patients, since this may help to develop and guide effective Cognitive treatments. Method: In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or a control group. Both CRT and MBCT consist of a structured 9-week program. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is subjective Cognitive complaints. Secondary outcome measures are objective Cognitive functioning, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion: To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive functioning among MS patients. In addition, studying the effect of CRT on Cognitive functioning may provide direction to the contradictory evidence that is currently available. This study will also provide information on functional brain network changes in relation to cognition. To conclude, this study may help to understand and treat Cognitive deficits among MS patients.

Bernard M. J. Uitdehaag - One of the best experts on this subject based on the ideXlab platform.

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC Neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Background Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. Methods/design In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. Trial registration This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial
    BMC neurology, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, Jeroen J. G. Geurts, Vincent De Groot, B. A. De Jong
    Abstract:

    Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive problems among MS patients, since this may help to develop and guide effective Cognitive treatments. In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective Cognitive complaints. Secondary outcome measures are objective Cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive function among MS patients. In addition, studying the effect of CRT on Cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to Cognitive function. To conclude, this study may help to understand and treat Cognitive problems among MS patients. This trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

  • Cognitive Rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): A study protocol for a randomised controlled trial
    Multiple Sclerosis Journal, 2017
    Co-Authors: Ilse M. Nauta, Anne E. M. Speckens, Roy P. C. Kessels, Bernard M. J. Uitdehaag, Luciano Fasotti, B. A. De Jong
    Abstract:

    Background: Cognitive deficits frequently occur in patients with multiple sclerosis (MS), which profoundly affect their quality of life. So far, the best Cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the efficacy of two promising non-pharmacological treatments: Cognitive Rehabilitation Therapy (CRT) and mindfulness-based Cognitive Therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of Cognitive deficits among MS patients, since this may help to develop and guide effective Cognitive treatments. Method: In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or a control group. Both CRT and MBCT consist of a structured 9-week program. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is subjective Cognitive complaints. Secondary outcome measures are objective Cognitive functioning, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. Discussion: To our knowledge, this will be the first RCT that investigates the effect of MBCT on Cognitive functioning among MS patients. In addition, studying the effect of CRT on Cognitive functioning may provide direction to the contradictory evidence that is currently available. This study will also provide information on functional brain network changes in relation to cognition. To conclude, this study may help to understand and treat Cognitive deficits among MS patients.